EL7.AI
StocksMedium•10 July 2026•
1 min read

Apollo to Invest $3.4 Billion in Bayer’s Contraceptives Business

Key Facts

1Apollo Global Management agreed to buy a minority stake in Bayer's long-acting reversible contraceptives (LARC) business.
2Bayer will secure €3 billion ($3.4 billion) in equity from Apollo-managed funds to bolster its capital structure.
3Bayer will preserve control over the contraceptives unit despite the equity investment from Apollo.

In a move aimed at addressing balance sheet challenges and reducing debt burdens, Bayer has agreed to sell a minority stake in its long-acting reversible contraceptives (LARC) business to Apollo Global Management. Under the agreement, the German pharmaceutical giant will secure €3 billion ($3.4 billion) in equity from Apollo-managed funds to bolster its capital structure. Bayer will maintain full operational control over the unit despite Apollo's entry as a minority shareholder.

This transaction occurs as major pharmaceutical firms increasingly restructure their portfolios, with the healthcare sector seeing similar private equity involvement, such as Blackstone's previous strategic investments in global healthcare units. Per market data, this capital injection allows Bayer to manage its financial obligations without divesting core strategic assets, providing a necessary buffer against ongoing legal pressures faced in other business segments.

In the equity markets, Bayer (BAYRY) stood at $14.44, while Apollo (APO) closed at $119.84 as of July 9, 2026. Investors are now watching how this liquidity will impact the German firm's credit profile, especially as the market anticipates key European economic catalysts, including a scheduled speech by Bundesbank's Joachim Nagel.